Zacks Investment Research downgraded shares of Quotient Ltd. (NASDAQ:QTNT) from a hold rating to a sell rating in a report issued on Wednesday morning.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Quotient (NASDAQ:QTNT) opened at 7.66 on Wednesday. The stock’s market cap is $110.12 million. The stock has a 50 day moving average of $7.49 and a 200-day moving average of $8.24. Quotient has a one year low of $5.67 and a one year high of $17.44.
In other Quotient news, Director L John Wilkerson acquired 180,000 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The stock was purchased at an average price of $5.50 per share, with a total value of $990,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider D J. Paul E. Cowan acquired 45,455 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The stock was acquired at an average cost of $5.50 per share, with a total value of $250,002.50. Following the acquisition, the insider now owns 26,666 shares of the company’s stock, valued at $146,663. The disclosure for this purchase can be found here. 40.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new position in Quotient during the first quarter worth approximately $105,000. First New York Securities LLC NY acquired a new position in Quotient during the second quarter worth approximately $140,000. Schonfeld Strategic Advisors LLC acquired a new position in Quotient during the first quarter worth approximately $172,000. BlackRock Investment Management LLC increased its position in Quotient by 2.5% in the second quarter. BlackRock Investment Management LLC now owns 86,418 shares of the company’s stock worth $670,000 after buying an additional 2,075 shares in the last quarter. Finally, Bellevue Group AG acquired a new position in Quotient during the first quarter worth approximately $880,000. 41.50% of the stock is owned by hedge funds and other institutional investors.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.